TY - JOUR
T1 - Endocrine treatment in breast cancer
T2 - Cure, resistance and beyond
AU - Tryfonidis, Konstantinos
AU - Zardavas, Dimitrios
AU - Katzenellenbogen, Benita S.
AU - Piccart, Martine
N1 - Publisher Copyright:
© 2016
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.
AB - Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment constituting its therapeutic cornerstone; despite its efficacy, endocrine resistance can develop, clinically as a relapse or a progression of the early or advanced disease respectively, hence necessitating alternative treatments. Over the last two decades, improved understanding of the molecular mechanisms of endocrine resistance has been achieved, with numerous targeted agents undergoing clinical development. Despite the multifactorial genesis of endocrine resistance, fuelled not only by alternative oncogenic signaling pathways of tumor cells, but also by tumor microenvironment-mediated mechanisms, successful clinical development of new agents has been recently noted. However, predictive biomarkers for accurate ‘navigation’ across the different treatment options are urgently needed. In this article, we present a thorough overview of the different clinical scenarios of BC endocrine resistance, and the recent advances in endocrine treatment, we describe the basic molecular mediators of endocrine resistance and the respective targeted agents undergoing clinical development; finally, we provide our perspective on the future of BC endocrine treatment.
KW - Endocrine treatment
KW - Molecular mechanisms
KW - New agents
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=84988040443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988040443&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2016.08.008
DO - 10.1016/j.ctrv.2016.08.008
M3 - Review article
C2 - 27643748
AN - SCOPUS:84988040443
SN - 0305-7372
VL - 50
SP - 68
EP - 81
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
ER -